Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8424448 | 0.91 | ITK (0.44) | HTR1AHTR1DHTR1BNTRK1ITK | |
| SCHEMBL8239964 | 0.84 | PARP1 (0.44) | PARP1HTR1AHTR1DHTR1BNTRK1 | |
| SCHEMBL8423849 | 0.81 | PDE3B (0.41) | NTRK1 | |
| SCHEMBL8424760 | 0.81 | CYP1A2 (0.41) | HTR1AHTR1DHTR1BNTRK1MPO | |
| SCHEMBL8424751 | 0.79 | PDE3B (0.41) | HTR1AHTR1DHTR1BNTRK1 | |
| SCHEMBL8424834 | 0.79 | HTR1A (0.41) | HTR1AHTR1DHTR1BMPO | |
| SCHEMBL8423782 | 0.77 | HRH4 (0.36) | NTRK1SLC6A4HTR2CKCNH2 | |
| SCHEMBL8424226 | 0.77 | MAPT (0.42) | NTRK1MPOHTR2C | |
| SCHEMBL8424587 | 0.76 | ROCK2 (0.36) | PARP1NTRK1 | |
| SCHEMBL3533331 | 0.74 | SIGMAR1 (0.40) | PARP1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | PARP1 3736/4885HTR1A 3/4885HTR1D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.